Vitrectomy for Localized Vitreous Seeds of Retinoblastoma in an Only Eye
Ji Xun-da,Lu Shang-lin,Zhao Pei-quan
DOI: https://doi.org/10.3760/cma.j.issn.0366-6999.20130425
IF: 6.133
2013-01-01
Chinese Medical Journal
Abstract:Vitreous seeds of retinoblastoma are one of the main reasons for treatment failure using globe-conserving therapy due to their poor response to therapy. This is most likely secondary to the difficulty for chemotherapeutic drugs to permeate into the vitreous cavity due to the bloodeye barrier.1 Currently, laser coagulation or cryotherapy is not used for vitreous seeds. External beam radiotherapy has been seldom used for vitreous seeds due to radiationrelated complications.2 Recently, several reports have showed repeated intravitreal injections of anticancer drugs, such as melphalan, may be an option for vitreous seeds.3 However, long-term efficacy of this approach is unsure and this treatment is unavailable at many treatment centers. Furthermore, repeated intravitreal injections entail an increased risk of extraocular dissemination of tumor cells. With the advances in technology and equipment for vitrectomy, the indications for surgery have also expanded. Vitrectomy has been performed to manage complications of conservative treatment for retinoblastoma, including rhegmatogenous retinal detachment, tractional retinal detachment with vitreous and epiretinal membranes, and vitreous hemorrhage.4 Here, we described a case of localized vitreous seeds of retinoblastoma that was successfully treated with vitrectomy. The patient described in this case was diagnosed with bilateral retinoblastoma at 6 months of age. The right eye was classified as group E according to the International classification of Retinoblastoma. The left eye was classified as group B. Enucleation had been performed on the right eye. The tumor in superior retina of the left eye had regressed to flat scar and calcification after four concurrent cycles of vincristine, etoposide, and carboplatin chemotherapy, four sessions of cryotherapy, and two sessions of laser coagulation. At 16 months of follow-up, one vitreous seed was noted (Figure 1A). Scarred tumor in the upper peripheral retina of the left eye was unchanged. However, increased vitreous seed growth had been noted during the subsequent followup of 6 months (Figure 1B). The patient underwent 23-gauge vitrectomy under wide field viewing for vitreous seeds after the consent was obtained. During the surgery, the localized vitreous seeds were removed first. To prevent vitreous seed movement due to the flow of irrigation fluid, we removed the vitreal seeds by vitreous cutter with dry vitrectomy technique. Then, core vitrectomy was regularly carried out. When vitrectomy for peritumoral vitreous cortex was performed, a cut rate of 2500 r/min and vacuum of 0-40 mmHg were set in order to avoid disturbance of tumor. Finally, 12% perfluoropropane gas tamponade was performed. The sclerotomies were closed using an 8-0 vicryl suture. During postoperative follow-up at 26 months, the tumor was stable and no vitreous seeds were noted (Figure 1C). There were no signs of orbital or systemic metastasis. The best-corrected visual acuity of the left eye was 120/200.Figure 1.: Fundus photograph of the left eye. A: After treatment with systemic chemotherapy, cryotherapy, and laser coagulation, the tumor in the upper peripheral retina regressed to flat scar and calcification, and one vitreous seed was noted (arrow). B: Localized vitreous seeds (arrowhead) demonstrated increased growth during the subsequent follow-up of 6 months. C: The tumor in the upper peripheral retina remained quiescent with no vitreous seeds 26 months after vitrectomy.Vitrectomy is an aggressive modality for mechanical removal of intraocular retinoblastoma due to the risk of tumor cell dispersion out from the sclerotomies and recurrence of intraocular tumor. It should be performed with caution. We recommend the following: (1) retinal tumor has been stable for enough time before vitrectomy. Previous reports have shown a decreased incidence of recurrence and metastatic disease in patients undergoing vitrectomy who had maintained tumor quiescence for a longer period.4 (2) A limited number of vitreous seeds. Localized vitreous seeds can be removed completely in visualization. Moderate to severe vitreous seeds will increase the risk of extraocular dispersion of tumor cells during surgery and incomplete removal of seeds. (3) The operation should be carried out by experienced pediatric vitrectomy surgeons. Vitrectomy in pediatric eyes presents unique challenge and is often different from that in adults. Familiarity with pediatric vitrectomy will lower complications of vitrectomy. Some complications such as retinal detachment, proliferative vitreoretinopathy, and vitreous hemorrhage require revitrectomy which in turn would increase the risk of recurrence and metastasis. Vitrectomy for vitreous seeds of retinoblastoma is different from that for noncancerous retinal disease. Some points should be kept in mind during the procedure. Pay attention to reduce the frequency of intraocular instrument exchange for minimizing intraocular fluid flow through the sclerotomies throughout the surgical procedure. Vitreous seeds should be removed at the beginning of the surgical procedure. Otherwise, vitreous seeds may float within the vitreous cavity and disperse to some invisible zones such as ciliary process and posterior surface of the iris due to intraocular fluid flow, resulting in incomplete removal of vitreous seeds. We recommend intraocular irrigation with anticancer drugs such as melphalan during vitrectomy, although it is not used in our patient. Optimal concentration of anticancer drugs in the vitreous cavity and subconjunctiva around the sclerotomies will reduce the risk of metastasis of tumor cells.5